Fig. 2

Elevated levels of endogenous AR induce appearance and increase of AR-Vs. A Fold change analysis (2 way ANOVA) of AR-FL and AR-Vs in LNCaP cells treated with enzalutamide for up to 14 days (*** represents p < 0.001, **** p < 0.0001). B Transcript copy number analysis of HEK293-T cells treated with CRISPR/dCas9 AR activation system. Shown are number of transcripts upon transfection with either scramble control plasmid (scr) or AR promotor specific guideRNA (gRNA). Numbers indicate number of positive samples within 10 transfections (ns represents p > 0.05, * p < 0.05, **** p < 0.0001). C Amplification curves of qPCR analyses of PC-3 and RWPE-1 cells treated with CRISPR/dCas9 AR activation system. Shown are amplification curves of AR-FL and AR-Vs. Cells were transfected with either scramble control plasmid (scr) or AR promotor specific guideRNA (gRNA)